高级检索
当前位置: 首页 > 详情页

The MDM2-p53-pyruvate carboxylase signalling axis couples mitochondrial metabolism to glucose-stimulated insulin secretion in pancreatic beta-cells

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE ◇ 自然指数

机构: [1]State Key Laboratory of Pharmaceutical Biotechnology, The University of Hong Kong, Pok Fu Lam, Hong Kong [2]Department of Medicine, The University ofHong Kong, Pok Fu Lam, Hong Kong [3]Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai 20032, China [4]Beijing Key Laboratory of Diabetes Research and Care, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China [5]Department ofBiochemistry and Molecular Biology, University of Southern Denmark, Odense 5230, Denmark [6]Department of Molecular Medicine, Mayo Clinic, Rochester,Minnesota 55905, USA [7]Department of Pharmacology & Pharmacy, The University of Hong Kong, Pok Fu Lam, Hong Kong
出处:
ISSN:

摘要:
Mitochondrial metabolism is pivotal for glucose-stimulated insulin secretion (GSIS) in pancreatic beta-cells. However, little is known about the molecular machinery that controls the homeostasis of intermediary metabolites in mitochondria. Here we show that the activation of p53 in beta-cells, by genetic deletion or pharmacological inhibition of its negative regulator MDM2, impairs GSIS, leading to glucose intolerance in mice. Mechanistically, p53 activation represses the expression of the mitochondrial enzyme pyruvate carboxylase (PC), resulting in diminished production of the TCA cycle intermediates oxaloacetate and NADPH, and impaired oxygen consumption. The defective GSIS and mitochondrial metabolism in MDM2-null islets can be rescued by restoring PC expression. Under diabetogenic conditions, MDM2 and p53 are upregulated, whereas PC is reduced in mouse beta-cells. Pharmacological inhibition of p53 alleviates defective GSIS in diabetic islets by restoring PC expression. Thus, the MDM2-p53-PC signalling axis links mitochondrial metabolism to insulin secretion and glucose homeostasis, and could represent a therapeutic target in diabetes.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2015]版:
大类 | 1 区 综合性期刊
小类 | 1 区 综合性期刊
最新[2023]版:
大类 | 1 区 综合性期刊
小类 | 1 区 综合性期刊
JCR分区:
出版当年[2014]版:
Q1 MULTIDISCIPLINARY SCIENCES
最新[2023]版:
Q1 MULTIDISCIPLINARY SCIENCES

影响因子: 最新[2023版] 最新五年平均 出版当年[2014版] 出版当年五年平均 出版前一年[2013版] 出版后一年[2015版]

第一作者:
第一作者机构: [1]State Key Laboratory of Pharmaceutical Biotechnology, The University of Hong Kong, Pok Fu Lam, Hong Kong [2]Department of Medicine, The University ofHong Kong, Pok Fu Lam, Hong Kong [3]Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai 20032, China
共同第一作者:
通讯作者:
通讯机构: [1]State Key Laboratory of Pharmaceutical Biotechnology, The University of Hong Kong, Pok Fu Lam, Hong Kong [2]Department of Medicine, The University ofHong Kong, Pok Fu Lam, Hong Kong [7]Department of Pharmacology & Pharmacy, The University of Hong Kong, Pok Fu Lam, Hong Kong
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:21434 今日访问量:0 总访问量:1221 更新日期:2025-02-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学附属北京同仁医院 技术支持:重庆聚合科技有限公司 地址:北京市东城区东交民巷1号(100730)